Kratom exposure is an emerging poisoning risk in dogs and cats: full analysis

Kratom is moving from fringe toxicology concern to a poisoning risk veterinary teams are more likely to encounter in everyday practice. A newly published JAVMA case series described 139 companion animals with incidental kratom exposure reported to the ASPCA Animal Poison Control Center between February 2014 and December 2024, including 128 dogs and nine cats. The authors found that ingestion was the primary route of exposure, with dogs most often showing lethargy, weakness, or sedation, vocalization, and hypersalivation or lip licking, while cats most commonly showed lethargy, mydriasis, and vocalization. (pubmed.ncbi.nlm.nih.gov)

That publication adds a firmer evidence base to the warning highlighted in VETgirl’s recent clinical education coverage: kratom is increasingly present in homes, marketed in multiple consumer-friendly forms, and capable of producing a wide range of signs in pets. FDA says there are no FDA-approved kratom drug products or over-the-counter drugs containing kratom legally marketed in the U.S., and the agency continues to warn consumers about serious adverse events linked to kratom use. FDA also notes that kratom products are sold through a fragmented supply chain, including online channels, smoke and vape shops, and small retailers, which can make household exposure harder for veterinary teams to anticipate and for pet parents to recognize as risky. (fda.gov)

The veterinary case data are still limited, but the new paper offers several useful specifics. Reported doses, when available, ranged from 1.2 mg/kg to 4,775 mg/kg, with a median of 203.5 mg/kg. Outcomes were unknown for most animals, which means the long-term prognosis remains unclear in the published dataset, even though the authors emphasized recognizable short-term clinical patterns. Their clinical takeaway was straightforward: veterinarians should consider kratom exposure in the differential diagnosis for nonspecific lethargy, vocalization, or nausea, especially where kratom is legally available. (pubmed.ncbi.nlm.nih.gov)

The broader exposure environment also helps explain why this matters now. ASPCA reported that its Animal Poison Control Center responded to more than 451,000 calls related to toxic substance, plant, and poison exposures in animals in 2024, nearly a 4% increase from the prior year. Over-the-counter medications remained the top toxin category, and vitamins and dietary supplements led that group. Kratom doesn’t appear as a standalone top-category toxin in that release, but it fits the same household-access pattern: human-use products left within reach, variable formulations, and pet parent assumptions that “natural” means safe. (aspca.org)

On the human public health side, surveillance suggests kratom exposures are increasing, not stabilizing. CDC’s 2026 MMWR analysis found 14,449 kratom exposure reports to U.S. poison centers from 2015 through 2025, with a record 3,434 reports in 2025, about a 1,200% increase from 2015. The report also found that multiple-substance exposures were associated with more hospitalizations, more serious outcomes, and most kratom-associated deaths. CDC linked the sharp 2025 increase with the emergence of high-potency semisynthetic formulations, including 7-hydroxymitragynine. That human trend doesn’t translate directly to pets, but it does suggest a growing volume and potency of kratom products in homes, which is a reasonable risk signal for veterinary medicine. (cdc.gov)

Expert perspective in veterinary toxicology is still developing, but the authorship of the new companion-animal paper is notable: it includes investigators from the University of Florida and the ASPCA Animal Poison Control Center. That collaboration gives the report practical relevance for clinicians, even with its limitations around incomplete outcome data. The paper’s signal is less about definitive prognosis and more about pattern recognition: if a dog presents sedate, nauseated, hypersalivating, or unusually vocal after possible access to supplements or powders, kratom now belongs on the history checklist. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, the practical issue is not just kratom itself, but the diagnostic blind spot around consumer botanicals and concentrated extract products. FDA says kratom contains multiple alkaloids, with research often focused on mitragynine and 7-hydroxymitragynine, and that these compounds can produce opioid-like effects such as sedation, nausea or vomiting, dependence or withdrawal, and respiratory depression in humans. In pets, the published clinical picture appears less fully defined, but the overlap with common emergency presentations means missed exposure histories are possible. Asking about powders, capsules, gummies, teas, and extract shots may become as important as asking about cannabis edibles or nicotine products. (fda.gov)

What to watch: The next step is likely more formal veterinary surveillance and better diagnostics. A 2025 University of Florida abstract described validation work for detecting mitragynine and 7-hydroxymitragynine in canine urine, suggesting clinicians may eventually have more practical tools to confirm suspected exposure. Until then, veterinary teams will likely rely on history, poison center consultation, and supportive care while the literature catches up with a poisoning risk that appears to be growing. (research.vetmed.ufl.edu)